guest ::
| Home > Publications database > Feasibility and antitumour activity of the FGFR inhibitor erdafitnib in three paediatric CNS tumour patients. > print |
| Home > Publications database > Feasibility and antitumour activity of the FGFR inhibitor erdafitnib in three paediatric CNS tumour patients. > print |
| 001 | 286717 | ||
| 005 | 20250523131928.0 | ||
| 024 | 7 | _ | |a 10.1002/pbc.30836 |2 doi |
| 024 | 7 | _ | |a pmid:38177074 |2 pmid |
| 024 | 7 | _ | |a 1545-5009 |2 ISSN |
| 024 | 7 | _ | |a 1545-5017 |2 ISSN |
| 037 | _ | _ | |a DKFZ-2024-00057 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Stepien, Natalia |0 0000-0002-6658-8367 |b 0 |
| 245 | _ | _ | |a Feasibility and antitumour activity of the FGFR inhibitor erdafitnib in three paediatric CNS tumour patients. |
| 260 | _ | _ | |a New York, NY |c 2024 |b Wiley |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1706169971_5733 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2024 Mar;71(3):e30836 |
| 520 | _ | _ | |a Alterations of the fibroblast growth factor (FGF) signalling pathway are increasingly recognized as frequent oncogenic drivers of paediatric brain tumours. We report on three patients treated with the selective FGFR1-4 inhibitor erdafitinib. Two patients were diagnosed with a posterior fossa ependymoma group A (PFA EPN) and one with a low-grade glioma (LGG), harbouring FGFR3/FGFR1 overexpression and an FGFR1 internal tandem duplication (ITD), respectively. While both EPN patients did not respond to erdafitinib treatment, the FGFR1-ITD-harbouring tumour showed a significant decrease in tumour volume and contrast enhancement throughout treatment. The tumour remained stable 6 months after treatment discontinuation. |
| 536 | _ | _ | |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312) |0 G:(DE-HGF)POF4-312 |c POF4-312 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a CNS tumours |2 Other |
| 650 | _ | 7 | |a ependymoma |2 Other |
| 650 | _ | 7 | |a erdafitinib |2 Other |
| 650 | _ | 7 | |a fibroblast growth factor receptor |2 Other |
| 650 | _ | 7 | |a internal tandem duplication (ITD) |2 Other |
| 650 | _ | 7 | |a low-grade glioma |2 Other |
| 650 | _ | 7 | |a paediatrics |2 Other |
| 700 | 1 | _ | |a Mayr, Lisa |b 1 |
| 700 | 1 | _ | |a Schmook, Maria T |b 2 |
| 700 | 1 | _ | |a Raimann, Adalbert |0 0000-0002-3551-594X |b 3 |
| 700 | 1 | _ | |a Dorfer, Christian |b 4 |
| 700 | 1 | _ | |a Peyrl, Andreas |0 0000-0002-5736-8231 |b 5 |
| 700 | 1 | _ | |a Azizi, Amedeo A |0 0000-0002-1347-6644 |b 6 |
| 700 | 1 | _ | |a Schramm, Kathrin |0 P:(DE-He78)2f592d9d8339bee07cca3956b7472b61 |b 7 |u dkfz |
| 700 | 1 | _ | |a Haberler, Christine |b 8 |
| 700 | 1 | _ | |a Gojo, Johannes |b 9 |
| 773 | _ | _ | |a 10.1002/pbc.30836 |g p. e30836 |0 PERI:(DE-600)2130978-4 |n 3 |p e30836 |t Pediatric blood & cancer |v 71 |y 2024 |x 1545-5009 |
| 856 | 4 | _ | |u https://inrepo02.dkfz.de/record/286717/files/Pediatric%20Blood%20Cancer%20-%202024%20-%20Stepien%20-%20Feasibility%20and%20antitumour%20activity%20of%20the%20FGFR%20inhibitor%20erdafitnib%20in%20three.pdf |
| 856 | 4 | _ | |u https://inrepo02.dkfz.de/record/286717/files/Pediatric%20Blood%20Cancer%20-%202024%20-%20Stepien%20-%20Feasibility%20and%20antitumour%20activity%20of%20the%20FGFR%20inhibitor%20erdafitnib%20in%20three.pdf?subformat=pdfa |x pdfa |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:286717 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 7 |6 P:(DE-He78)2f592d9d8339bee07cca3956b7472b61 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-312 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Funktionelle und strukturelle Genomforschung |x 0 |
| 914 | 1 | _ | |y 2024 |
| 915 | _ | _ | |a DEAL Wiley |0 StatID:(DE-HGF)3001 |2 StatID |d 2023-10-25 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b PEDIATR BLOOD CANCER : 2022 |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-10-25 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-10-25 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2023-10-25 |
| 920 | 1 | _ | |0 I:(DE-He78)B360-20160331 |k B360 |l Pädiatische Gliomforschung |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)B360-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|